Kamfanin fasahar likitanci ya mai da hankali kan haɓaka sabbin fasahohi don gano cutar kansa da wuri, a yau ya sanar da sabon sakamakon bincike. Nazarin asibiti na ciwon hanta ya nuna babban yuwuwar LAM's sabon DNA methylation-based biomarker don gano carcinoma hepatocellular (HCC) Haɓakar ganowa shine 95% kuma takamaiman shine 97.5%.
A cikin wannan binciken, an tattara samfuran samfurori na batutuwa 130, ciki har da: 60 batutuwa da aka gano tare da ciwon daji na hepatocellular (mataki na I zuwa IV), batutuwa 30 ba tare da cutar hanta ba, 10 batutuwa da aka gano tare da ciwon hanta mara kyau da kuma batutuwa 30 da aka gano tare da ciwon nono, ciwon daji na colorectal. ko ciwon huhu. An fitar da DNA daga samfurin, an canza DNA da bisulfite, kuma an ƙididdige DNA methylation ta amfani da dandalin IvyGene. Bayan kammala tattara bayanai da nazarin duk samfuran, makantar da samfuran don ƙididdige aikin gwajin.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of maganin ciwon daji samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
